| abstract |
Disclosed herein are 2-arylpropionic acid derivatives of formula (I) wherein the substituents are as defined in the specification. Such compounds compounds show a surprising potent inhibitory effect on C5a induced human PMN chemotaxis. Said compounds are useful in the treatment of pathologies depending on the chemotactic activation of neutrophils and monocytes induced by the fraction C5a of the complement. In particular, the compounds are useful in the treatment of sepsis, psoriasis, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of injury caused by ischemia and reperfusion. |